DXR vs. ARAY, DRTS, CVRX, CLPT, QIPT, TELA, BWAY, BLUA, KRMD, and SRTS
Should you be buying Daxor stock or one of its competitors? The main competitors of Daxor include Accuray (ARAY), Alpha Tau Medical (DRTS), CVRx (CVRX), ClearPoint Neuro (CLPT), Quipt Home Medical (QIPT), TELA Bio (TELA), BrainsWay (BWAY), BlueRiver Acquisition (BLUA), KORU Medical Systems (KRMD), and Sensus Healthcare (SRTS). These companies are all part of the "surgical & medical instruments" industry.
Accuray (NASDAQ:ARAY) and Daxor (NASDAQ:DXR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, community ranking, dividends, analyst recommendations, profitability and media sentiment.
Accuray received 331 more outperform votes than Daxor when rated by MarketBeat users.
Daxor has lower revenue, but higher earnings than Accuray.
Accuray has a beta of 1.48, indicating that its stock price is 48% more volatile than the S&P 500. Comparatively, Daxor has a beta of -0.45, indicating that its stock price is 145% less volatile than the S&P 500.
In the previous week, Accuray had 2 more articles in the media than Daxor. MarketBeat recorded 5 mentions for Accuray and 3 mentions for Daxor. Daxor's average media sentiment score of 0.92 beat Accuray's score of 0.72 indicating that Accuray is being referred to more favorably in the media.
64.1% of Accuray shares are owned by institutional investors. Comparatively, 1.3% of Daxor shares are owned by institutional investors. 3.8% of Accuray shares are owned by insiders. Comparatively, 60.6% of Daxor shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Daxor has a net margin of 0.00% compared to Daxor's net margin of -4.99%. Accuray's return on equity of 0.00% beat Daxor's return on equity.
Accuray presently has a consensus target price of $8.25, indicating a potential upside of 366.10%. Given Daxor's higher probable upside, analysts clearly believe Accuray is more favorable than Daxor.
Summary
Accuray beats Daxor on 8 of the 12 factors compared between the two stocks.
Get Daxor News Delivered to You Automatically
Sign up to receive the latest news and ratings for DXR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DXR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
